Trial to compare two Genentech drugs

02/22/2007 | Wall Street Journal, The

Genentech is urging doctors to use its Lucentis drug to treat age-related macular degeneration, but some doctors choose to use Genentech's cancer drug Avastin instead, even though Avastin is not FDA-approved to treat eye problems. The federal government is stepping in by conducting an NIH-funded comparison trial of the two biotech drugs. BIO argues that the NIH should study cutting-edge science rather than spend money to compare two approved drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY